Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?

    ... Braulke F, Kündgen A et al. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk ... even if used, unfortunately yield low responses. While azacitidine prolongs survival in patients with HR-MDS by a median of 9.5 ... responses only occur in less than half of the patients, and azacitidine therapy is not curative, with most patients relapsing within 2 ...

    Research Article last updated 06/28/2013 - 1:24pm.

  2. Recent developments in myelodysplastic syndromes

    ... in the United States (US). US regulatory approval of azacitidine , decitabine , and lenalidomide between 2004 and ...

    Research Article last updated 04/29/2016 - 11:34am.

  3. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial.

    ... The phase III AZA-001 study established that azacitidine significantly improves overall survival compared with ... disease progression). Achieving an Overall Response with azacitidine reduced risk of death by 95% compared with achieving an Overall ...

    Research Article last updated 05/14/2013 - 2:51pm.

  4. Myelodysplastic syndromes: Contemporary review and how we treat

    ... limited; they include the hypomethylating agents (HMA) azacitidine and decitabine and lenalidomide for MDS with ...

    Research Article last updated 04/29/2016 - 1:05pm.

  5. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine

    ... Center Clinical Database who received lenalidomide and azacitidine after ESA treatment failure. Rates of erythroid hematologic ... in patients who received lenalidomide first followed by azacitidine (group 1) and those who received lenalidomide after azacitidine ...

    Research Article last updated 12/09/2015 - 8:59am.

  6. Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.

    ... Outcome of patients with myelodysplastic syndrome after azacitidine failure is poor. In this population, we combined cytarabine ...

    Research Article last updated 09/03/2013 - 12:32pm.

  7. Shelf-life Extension of Azacitidine: Waste and Cost Reduction in the Treatment of Myelodysplastic Syndromes

    ...

    Research Article last updated 06/19/2014 - 1:26pm.

  8. Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: a practice standard for Canadian nurses

    ... von Riedemann S, Kurtin S; Canadian Nurses Working Group on Azacitidine in MDS Original Publication Date:  ...

    Research Article last updated 03/05/2013 - 9:33am.

  9. Real-Life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile

    ...

    Research Article last updated 02/04/2014 - 1:52pm.

  10. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

    ...

    Research Article last updated 02/04/2013 - 2:29pm.